Which has better valuation and earnings, COAG or SRRK?

Scholar Rock is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$24.78 N/A Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is COAG or SRRK more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Scholar Rock N/A -160.19% -87.18%

Does the media refer more to COAG or SRRK?

In the previous week, Scholar Rock had 6 more articles in the media than Hemab Therapeutics. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.63 beat Scholar Rock's score of 0.40 indicating that Hemab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, COAG or ORKA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$24.78 N/A Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A

Is COAG or ORKA more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Oruka Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Oruka Therapeutics N/A -21.65% -20.88%

Does the media prefer COAG or ORKA?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Oruka Therapeutics and 3 mentions for Hemab Therapeutics. Oruka Therapeutics' average media sentiment score of 0.79 beat Hemab Therapeutics' score of 0.63 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or COAG?

In the previous week, Mirum Pharmaceuticals had 21 more articles in the media than Hemab Therapeutics. MarketBeat recorded 24 mentions for Mirum Pharmaceuticals and 3 mentions for Hemab Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.72 beat Hemab Therapeutics' score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 8 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, COAG or COGT?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$24.78 N/A Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A

Is COAG or COGT more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Cogent Biosciences N/A -84.47% -47.72%

Does the media refer more to TVTX or COAG?

In the previous week, Travere Therapeutics had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 5 mentions for Travere Therapeutics and 3 mentions for Hemab Therapeutics. Travere Therapeutics' average media sentiment score of 0.91 beat Hemab Therapeutics' score of 0.63 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hemab Therapeutics (COAG) Competitors

$29.49 -0.31 (-1.04%)

As of 12:07 PM Eastern

Compare

COAG vs. SRRK, ORKA, MIRM, COGT, and TVTX

Should you buy Hemab Therapeutics stock or one of its competitors? Hemab Therapeutics's main competitors and comparable companies include Scholar Rock (SRRK), Oruka Therapeutics (ORKA), Mirum Pharmaceuticals (MIRM), Cogent Biosciences (COGT), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Hemab Therapeutics compare to Scholar Rock?

Hemab Therapeutics (NASDAQ:COAG) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Hemab Therapeutics currently has a consensus price target of $52.17, suggesting a potential upside of 75.06%. Scholar Rock has a consensus price target of $67.67, suggesting a potential upside of 67.00%. Given Hemab Therapeutics' higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	2.94

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Scholar Rock had 6 more articles in the media than Hemab Therapeutics. MarketBeat recorded 9 mentions for Scholar Rock and 3 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.63 beat Scholar Rock's score of 0.40 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scholar Rock is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Hemab Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Scholar Rock	N/A	-160.19%	-87.18%

Summary

Scholar Rock beats Hemab Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Hemab Therapeutics compare to Oruka Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

56.4% of Oruka Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Oruka Therapeutics and 3 mentions for Hemab Therapeutics. Oruka Therapeutics' average media sentiment score of 0.79 beat Hemab Therapeutics' score of 0.63 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hemab Therapeutics' return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Oruka Therapeutics	N/A	-21.65%	-20.88%

Hemab Therapeutics presently has a consensus price target of $52.17, indicating a potential upside of 75.06%. Oruka Therapeutics has a consensus price target of $128.91, indicating a potential upside of 64.87%. Given Hemab Therapeutics' higher possible upside, equities analysts clearly believe Hemab Therapeutics is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Oruka Therapeutics beats Hemab Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Hemab Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Mirum Pharmaceuticals currently has a consensus target price of $146.63, suggesting a potential upside of 84.16%. Hemab Therapeutics has a consensus target price of $52.17, suggesting a potential upside of 75.06%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Mirum Pharmaceuticals is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Mirum Pharmaceuticals had 21 more articles in the media than Hemab Therapeutics. MarketBeat recorded 24 mentions for Mirum Pharmaceuticals and 3 mentions for Hemab Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.72 beat Hemab Therapeutics' score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	8 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hemab Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Hemab Therapeutics' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Hemab Therapeutics	N/A	N/A	N/A

Hemab Therapeutics has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	9.92	-$23.36M	-$14.55	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Summary

Mirum Pharmaceuticals beats Hemab Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Hemab Therapeutics compare to Cogent Biosciences?

Hemab Therapeutics (NASDAQ:COAG) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Hemab Therapeutics had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 3 mentions for Hemab Therapeutics and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat Hemab Therapeutics' score of 0.63 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Hemab Therapeutics	Positive
Cogent Biosciences	Very Positive

Hemab Therapeutics presently has a consensus price target of $52.17, suggesting a potential upside of 75.06%. Cogent Biosciences has a consensus price target of $51.56, suggesting a potential upside of 83.54%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Hemab Therapeutics' return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Cogent Biosciences	N/A	-84.47%	-47.72%

Cogent Biosciences is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Summary

Cogent Biosciences beats Hemab Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Hemab Therapeutics compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Travere Therapeutics presently has a consensus target price of $69.50, indicating a potential upside of 34.17%. Hemab Therapeutics has a consensus target price of $52.17, indicating a potential upside of 75.06%. Given Hemab Therapeutics' higher probable upside, analysts clearly believe Hemab Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Hemab Therapeutics has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	9.95	-$25.55M	-$0.46	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

In the previous week, Travere Therapeutics had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 5 mentions for Travere Therapeutics and 3 mentions for Hemab Therapeutics. Travere Therapeutics' average media sentiment score of 0.91 beat Hemab Therapeutics' score of 0.63 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hemab Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Hemab Therapeutics' return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Hemab Therapeutics	N/A	N/A	N/A

Summary

Travere Therapeutics beats Hemab Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Hemab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COAG vs. The Competition

Export

Metric	Hemab Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.38B	$3.89B	$7.28B	$13.01B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-1.19	12.99	275.44	25.42
Price / Sales	N/A	1,141.69	559.80	78.81
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	N/A	16.88	10.66	5.96
Net Income	N/A	-$22.65M	$3.50B	$380.62M
7 Day Performance	2.75%	-5.64%	-3.65%	-3.75%
1 Month Performance	-27.13%	-13.53%	-8.06%	-6.62%
1 Year Performance	N/A	6.87%	2.58%	-4.38%

Hemab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COAG Hemab Therapeutics	2.962 of 5 stars	$29.49 -1.0%	$52.17 +76.9%	N/A	$1.38B	N/A	N/A	59	Analyst Upgrade
SRRK Scholar Rock	3.1123 of 5 stars	$46.81 +1.4%	$66.75 +42.6%	+18.2%	$5.70B	N/A	N/A	289
ORKA Oruka Therapeutics	2.66 of 5 stars	$84.52 +1.3%	$128.91 +52.5%	+206.6%	$5.60B	N/A	N/A	68	Analyst Forecast Insider Trade
MIRM Mirum Pharmaceuticals	3.0949 of 5 stars	$82.93 -1.2%	$142.56 +71.9%	+10.3%	$5.38B	$521.31M	N/A	433	Trending News Analyst Forecast Analyst Revision
COGT Cogent Biosciences	2.853 of 5 stars	$31.02 -1.8%	$51.56 +66.2%	+73.4%	$5.38B	N/A	N/A	258	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COAG) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemab Therapeutics (COAG) Competitors

COAG vs. SRRK, ORKA, MIRM, COGT, and TVTX

How does Hemab Therapeutics compare to Scholar Rock?

Summary

How does Hemab Therapeutics compare to Oruka Therapeutics?

Summary

How does Hemab Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Hemab Therapeutics compare to Cogent Biosciences?

Summary

How does Hemab Therapeutics compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemab Therapeutics (COAG) Competitors

COAG vs. SRRK, ORKA, MIRM, COGT, and TVTX

How does Hemab Therapeutics compare to Scholar Rock?

Do analysts rate COAG or SRRK?

Do insiders & institutionals hold more shares of COAG or SRRK?

Does the media refer more to COAG or SRRK?

Which has better valuation and earnings, COAG or SRRK?

Is COAG or SRRK more profitable?

Summary

How does Hemab Therapeutics compare to Oruka Therapeutics?

Which has preferable valuation and earnings, COAG or ORKA?

Do insiders and institutionals believe in COAG or ORKA?

Does the media prefer COAG or ORKA?

Is COAG or ORKA more profitable?

Do analysts rate COAG or ORKA?

Summary

How does Hemab Therapeutics compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or COAG?

Does the media prefer MIRM or COAG?

Is MIRM or COAG more profitable?

Which has better earnings and valuation, MIRM or COAG?

Summary

How does Hemab Therapeutics compare to Cogent Biosciences?

Does the media prefer COAG or COGT?

Do analysts prefer COAG or COGT?

Is COAG or COGT more profitable?

Which has stronger earnings & valuation, COAG or COGT?

Summary

How does Hemab Therapeutics compare to Travere Therapeutics?

Do analysts prefer TVTX or COAG?

Which has higher earnings and valuation, TVTX or COAG?

Does the media refer more to TVTX or COAG?

Is TVTX or COAG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools